LDRT and Chemoimmunotherapy in NPC With Liver Metastasis

This study aims to evaluate the efficacy and toxicity of adding low-dose radiotherapy to chemoimmunotherapy as a first-line treatment for nasopharyngeal carcinoma patients with liver metastasis.

Trial Details

NCT ID
NCT06788002
Phase
PHASE2
Sponsor
Hunan Cancer Hospital
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Low-dose radiotherapy combine with chemoimmunotherapy
Locations (sample)
  • Changsha, Hunan, China|28.19874,112.97087
  • Changsha, Hunan, China|28.19874,112.97087
  • Changsha, Hunan, China|28.19874,112.97087
  • Changsha, Hunan, China|28.19874,112.97087
  • Chenzhou, Hunan, China|25.8,113.03333

Key Eligibility Criteria

  • Age ≥ 18 years and ≤ 70 years, male or non-pregnant female.
  • Histologically confirmed with nonkeratinizing carcinoma of the nasopharynx (differentiated or undifferentiated type, WHO II or III)
  • Stage IVB (AJCC 8th edition staging)
  • De novo nasopharyngeal carcinoma with liver metastasis, or patients who had received curative treatment (radical radiotherapy or radical radiothera…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →